5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists

1 12 12 13 34 12 2 13 13 12 12 3 14 24 24 36 236 24 14 14 14 212 12 The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein "---" is absent or is optionally a bond; q is 1 or 2; Ris independently selected from hydrogen, -C-Calkyl, halo, hydroxy, -C-Chaloalkyl, -C-Calkoxy, cyano, -O-C-Ccycloalkyl, and -OC-Chaloalkyl; Ris selected from the group consisting of hydrogen, -C-Calkyl, hydroxy, -C-Calkoxy, cyano, -C-Chaloalkyl, -OC-Chaloalkyl, and halo; Ris selected from the group consisting of hydrogen, -C-Calkyl, -C-Chaloalkyl, -C-CalkylOH, -C-Ccycloalkyl, -CHC-Ccycloalkyl, -C-Calkyl-O-C-Calkyl, -C(O)C-Calkyl, -C(O)C-Chaloalkyl, -CH-thiazole, phenyl, benzyl, tetrahydrothiopyranyl, and tetrahydropyranyl, wherein the cycloalkyl, tetrahydrothiopyranyl, tetrahydropyranyl and thiazolyl group is optionally substituted with one or two groups independently selected from the group consisting of halo, hydroxy, C-Calkyl, and -C-Chaloalkyl; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof, useful in the treating, preventing or ameliorating of symptoms associated with obesity and related diseases.